EpiVakKorona OK’d in Turkmenistan


The Russian anti-COVID-19 EpiVakKorona of the Vector center is registered in Turkmenistan, Rospotrebnadzor reports.

“Within the framework of Russian-Turkmen cooperation on the prevention and control of infectious diseases in Ashgabat, Central Research Institute of Epidemiology of Rospotrebnadzor specialists continue to work to provide scientific and advisory assistance,” the supervisory authority said.

The EpiVacCorona vaccine, registered in September, is a peptide vaccine. The vaccination course provides for two-fold intramuscular administration with an interval of 14-21 days. According to the results of two phases of clinical studies, the immunological effectiveness (antibody formation) of the vaccine was 100%, Rospotrebnadzor reported.

On December 8, vaccine documents were transferred by the Russian authorities to the World Health Organization.